being, interferes with the doctor's therapeutic efforts, and leads to wasted health resources.1 Estimates of noncompliance rates with prescribed therapeutic regimens typically range from 30% to 60%, with most researchers agreeing that at least 50% of patients for whom drugs are prescribed fail to receive full benefit through inadequate adherence.2 Moreover, it has been estimated that almost one third of patients who received prescriptions were using them in a manner that posed a serious threat to their health.3 Yet, doctors infrequently suspect that their patients are not taking their drugs exactly as prescribed; patients rarely volunteer this information to their doctor, and doctors do not often explicitly ask. 4 On both a conceptual and methodological level, patient compliance presents difficult issues. Several authors have suggested that the term compliance reflects a biomedical paradigm that reinforces patient passivity and stigmatizes independent patient judgment about self-treatment as deviant.1 5 An alternative term, adherence, has been offered by some investigators to denote a more active patient-physician treatment collaboration than compliance. Most medical recommendations require some degree of independent patient judgment and accommodation. Although this is particularly true for lifestyle changes and preventive practices, most drug regimens also allow for some flexibility and patient discretion in how and when the drugs are taken. Although it is important to consider the behavioral dynamics of compliance broadly to include active collaboration, we have used the term compliance in this review because it is the most widely recognized term describing this body of literature both currently and historically. 1 Since the first major academic symposium on patient compliance at McMaster University in 1974, hundreds of studies have been conducted to improve understanding of patient and provider behavior in this regard.6 Many of these studies have investigated specific interventions that have led to substantial and meaningful increases in compliance and subsequent patient health status. The many published studies tend to be fragmented by diagnostic categories and disciplinary perspectives. For instance, insight into the compliance difficulties of the hypertensive patient has been less than optimally integrated into work with diabetic, asthmatic, or arthritic patients, although there is clearly common ground. Further, the potential effectiveness of health education interventions has been limited by inconsistent application of learning and behavioral change principles and a lack of systematic planning. 7 There have been a number of compliance-related meta-analytic reviews, most of which have been limited to the study of patients with particular chronic conditions, particular aspects of compliance such as appointment keeping, or a specific type of intervention, such as financial incentives.7-15 Influenced by the seminal work of Sackett and Haynes,6 many reviews limit the selection and evaluation of interventions to those few studies that meet the strictest criteria of methodological rigor.16 Consequently, few meta-analytic reviews simultaneously assess the nature and relative effectiveness of compliance interventions across the broad spectrum of patient conditions and compliance measures. The reviews infrequently have described the interventions in more than the most general manner, and the compliance outcomes have been summarized in either very narrow or widely inclusive terms.
The current meta-analytic review has been designed to provide a systematic synthesis of the compliance literature within a simple conceptual framework designed to facilitate a wider application and adaptation of effective compliance interventions. Further, the most common kinds of compliance outcomes have been distinguished so that intervention effectiveness for particular aspects of compliance can be specified.
Methods

Search Procedure and Criteria for Study Inclusion
To be included in the meta-analysis, a study had to meet the following criteria:
1. The study included at least one intervention, defined as a systematic attempt to influence or improve compliance with therapeutic recommendations; 2. A control group was included, which was defined as a comparison group comparable in all obvious ways to the intervention group(s); 3. Compliance with therapeutic recommendations or a health outcome linked to compliance was quantitatively measured; 4. The association between compliance and at least one intervention variable was reported or could be calculated. As described in detail below, this association is referred to in terms of magnitude of association or effect size (ES) and its statistical significance; 5. Sample size was 10 or greater; and 6. The study was published in an Englishlanguage journal between the years 1979 and 1994.
Studies published before 1979 were not included in this review because they had been reviewed in the extensive bibliography and evaluation of compliance literature conducted by Haynes et al. 6 Studies were identified through the following search methods: online database searches (MEDLINE) using the key words "patient compliance" (restricted to focus, major key word, or title word) crossed with "intervention" (in title or abstract); search of the Medication Use Studies (MUST) database,* and review of the bibliographies of other reviews. Review of the 1,040 identified articles yielded a final base of 162 that met selection criteria and for which effect sizes could be calculated.
In compiling the database, a distinction was drawn between an article and a study. A study comprises all the analyses of a given group of research subjects. These analyses may be described in more than one article. In instances in which the same group of subjects was referred to in more than one article, they were considered as part of a single study. When different results pertaining to the research subjects of a single study were published in more than one article, all such articles were included, but the data were combined to reflect the fact that only one sample of subjects was involved. Redundant results were not included. There were 153 studies represented in the 162 articles.
Coding of Study Characteristics
Overview. A coding scheme was devised to capture descriptive information about the studies. Coded information included study size, subject age and gender (very few studies reported subject ethnicity, socioeconomic status, occupation, or marital status), study design, study setting, and targeted diagnosis. The intervention was described in detail, including the focus of the intervention (educational, behavioral, affective, or provider targeted), strategies used to deliver the *The MUST database is made available to schools of pharmacy through educational grants from various pharmaceutical companies. intervention (such as one-to-one education, group education, or self-monitoring), and the number of intervention strategies used. Appendixes A, B, C, and D show the primary coding categories and the number of studies in each of them.
Study Size. Sample size varied widely from 20 to 75,853 subjects. The outlier study included all female patients of general practitioners in a large geographic area who had not received adequate preventive services. Because of the extreme value of the outlier, more than nine times the next highest value, we calculated the average study sample size mean with and without it to assess its effect on the body of reviewed studies; however, we did not exclude this study from any analysis. With the outlier, the studies had an average sample size of 873 (median, 150; mode, 100). Without the outlier, the average was reduced by more than half to 376 subjects, with a range from 20 to 8,298 (median, 150; mode, 100).
Subject Characteristics. In the database, 55 studies involved adult subjects, (> 18 years -< 65 years), seven involved elderly subjects (> 65 years), and 59 involved mixed populations of adult and elderly. Twenty-two studies were directed toward children or adolescents and/or their caretakers, and 10 studies targeted providers. Sufficient information about subject age was provided in all but three studies.
Most studies (n = 103) were performed with both male and female subjects, 15 were directed toward female subjects only, and six were male subjects only. Twenty-nine studies did not report information on subject gender. Study Design. Randomized trials accounted for 116 of the reviewed studies; 37 studies were nonrandom comparisons of control and treatment groups. The sample size of the trials varied widely. Nonrandomized studies were much larger than randomized studies (mean for nonrandomized studies = 3,306, median = 220, mode = 100, range = 22-75,831; mean for randomized studies = 412, median = 120, mode = 150, range = 20-8,298), although both kinds of studies included sample sizes of many thousands. A second distinction between randomized and nonrandom studies was the number of interventions and intervention permutations evaluated. The nonrandom studies produced 92 intervention comparisons, an average of 2.5 per study, whereas the 116 randomized studies produced 433 comparisons, an average of 3.7 per study.
The comparisons within studies were often complex. Slightly more than half the studies (n = 81) reported results evaluating the effects of a single intervention, whereas the remainder evaluated multiple treatment groups. Thirty studies evaluated two different interventions, 32 evaluated three different interventions, and 10 presented analysis of four or more different compliance interventions.
Study setting. The studies were conducted in a variety of places, with the majority taking place in university outpatient departments (n = 38), community outpatient departments (n = 44), combinations of university and community outpatient departments (n = 13), or in communitybased physicians' offices, including HMO offices (n = 17). Community settings were used in 10 studies (eg, a supermarket parking lot, work site, and senior center). Hospital inpatients were targeted in 16 studies, and nine studies were directed toward emergency room patients. Six studies were conducted in pharmacies.
Diagnoses. The diagnostic categories of the 153 studies are listed in Appendix A. The studies represent a variety of acute and chronic diagnoses, preventive activities, and physical and mental aspects of illness. Sixteen studies were not focused on any particular diagnosis, but referred rather to general categories of patients as: "all patients discharged from the hospital," "all patients receiving a prescription for an antibiotic," or "all emergency department patients."These were grouped under the unspecified category. Study interventions aimed at prevention of an illness, immunization, or periodic screening were coded under preventive services and represented the largest single category (n = 31), followed by interventions targeting hypertension (n = 24), mental health (n = 13), and diabetes (n = 12). Studies targeting patients with abnormal test results were coded under the appropriate diagnostic category (ie, abnormal Pap smear was coded as cancer).
Programmatic Focus and Intervention
Strategies. Interventions were grouped into broad programmatic categories, reflecting differences in the predominant theoretical focus or target of the intervention (Appendix B). The primary groupings were educational, behavioral, and affective. In addition, a fourth category of interventions directed toward providers was distinguished from patient education interventions.
The educational category reflects pedagogic interventions, verbal or written, with a knowledgebased emphasis designed to convey information. Specific strategies included one-to-one and group teaching, the use of written and audiovisual materials, mailed materials, and telephone instruction. Behaviorally focused interventions were designed to change compliance by targeting, shaping, or reinforcing specific behavioral patterns. This included strategies such as skill building and practice activities, behavioral modeling and contracting, packaging and dosage modifications or tailoring, rewards, and both mail and telephone reminders. Affectively focused strategies attempted to influence compliance through appeals to feelings and emotions or social relationships and social supports. Included were family support, counseling, and supportive home visits.
Provider interventions were directed toward physicians, with the exception of one study directed toward nurses and a second directed toward pharmacists. The interventions were either educational programs designed to help the provider improve patient compliance through better instruction or communication or behavioral interventions, usually based on the provision of reminders to the physician to address preventive services with their patients. Although these efforts could be combined into the broader programmatic categories of education and behavior, they were kept distinct so that the effects of patient education and provider education could be evaluated separately.
For interventions with a single primary programmatic focus, educational interventions (n = 50) were somewhat more frequent than behavioral interventions (n = 43). Many studies evaluated multiple interventions, which included varying combinations of educational, behavioral, and affective strategies. Very often the interventions reflected a combination of both educational and behavioral components (n = 32). Affective interventions by themselves were quite rare (n = 4), but they were more frequently investigated in combination with educational or behavioral components (n = 13). Interventions directed toward providers were as likely to be a single intervention (n = 5) as an intervention combined with other patient education or behavioral programmatic components (n = 5). The variety of strategies used within each of the areas of programmatic focus is shown in Appendix C.
Compliance Measures
Compliance was assessed or imputed in the studies through a variety of direct and indirect measures, as reflected in Appendix D. These were categorized to broadly represent five classes of compliance-related assessments: (1) Although not included as a compliance outcome, many studies (n = 24) also reported changes in patients'knowledge levels as a consequence of compliance interventions. Because these data were available, they are reported.
Studies used between one and five different compliance measures in their assessment of intervention effect. More than half of the studies (58%) used only one measure, approximately one quarter used two measures, 10% used three measures, 4% used four measures, and only one study used five measures.
Statistical Approach
An effect size (ES, defined as the Pearson correlation coefficient or r) representing the association between compliance intervention (intervention versus comparison group) and compliance outcome was calculated for all studies and used as an estimate of the strength or magnitude of each intervention's effect. The r statistic is one of several alternative measures of effect size used in meta-analytic summaries. Because differences were not equally detectable over the range of possible correlation coefficients (0.0-1.0), the Fisher's Z transformation was used.17 The resulting ESs have been transformed back to correlation coefficients in the tables. In the database, when r was not reported directly, it was calculated from the published information using standard formulas (eg, means and standard deviations, frequencies or percentages, %2, Student's t test, or F-test).17 Two coders independently calculated all ESs and resolved discrepancies through recalculation.
Standard meta-analytic procedures assume that results within a given analysis are independent. Our sorting of articles into their respective studies (see above) ensured that, for any given analysis of intervention and outcome, all of the summarized results would be based on independent intervention samples. As is frequently the case in meta-analyses, however, the same studies may appear in more than one analysis; for example, a given study would be included in the analysis of health outcomes and the analysis of direct indicators of compliance if that study used both kinds of outcome measures. Thus, different analyses are not wholly independent of each other. An additional qualification of the independence assumption is that within an analysis, the same control (untreated or comparison) sample could be used to test the effectiveness of more than one intervention.
Because the number of subjects in a given study varied tremendously, both an unweighted mean and a weighted (by sample size) mean ES were calculated for each analysis reported below.
Comparison between the weighted and unweighted mean ES helps to interpret the range and diversity of study findings. The most commonly reported "average" ES is the weighted mean, where weighting is by the study's sample size. When the weighted and unweighted means agree, an estimate of the average ES can be made with confidence. When they are not in agreement, however, special care must be taken in noting the discrepancy.18
The significance of combined ESs is presented through calculation of a combined Z. The combined Z is based on the P values (probability levels) associated with each study and is therefore a partial function of the number of subjects in each study rather than simply the number of studies included in the analysis. This approach corresponds to a fixed-effects test and has considerably greater statistical power than random effects tests such as 95% confidence intervals (CI), which are based on the number of studies entered into an analysis rather than on the number of subjects within a given study.17 If an author reported a result as "nonsignificant" and gave no other useful data for calculation of Z, a Z of zero was used to calculate the combined probability (sum of Z's divided by the square root of the N of studies).
A final consideration in the presentation of results is the magnitude of the ES. Cohen's19 rule of thumb for ES r considers 1 to <0.3 as small, 0.3 to <0;5 as medium, and 0.5 and greater as large. In addition to magnitude, Rosenthal20 has suggested that practical importance and clinical significance be considered. The binomial effect-size display (BESD) casts ES results into dichotomous outcomes, such as success versus failure or change versus no change, and is a way to display the intervention effect on success rate, however measured.20 The BESD for the treatment group is computed as 0.50 + (/2), whereas the control group success rate is computed as 0.50 -(/2); an r of 0.30 (considered medium magnitude) therefore is associated with a success rate of 30% for intervention group above that of a comparable control group (65% for the intervention group compared with 35% for the control group). Even a weak r of 0.2 (considered small magnitude) translates to a 20% added benefit for treatment groups compared with a control group. This modest advantage can carry appreciable clinical and practical implications when the outcome is as important as survival, hospitalization, or disease severity.
Results
Because many studies reported multiple compliance outcomes, the summary of results presented in the following tables are not fully independent. Results can be considered independent within a column in Tables 2 through 4 (with the caution that comparisons within a single study may have been made against a common control group), but not across columns because the same sample could have been used in the assessment of multiple compliance outcomes. Nevertheless, comparisons across columns are instructive in providing a perspective on the relative impact of interventions on the variety of outcome measures.
Overall Effects
As indicated in Table 1 , interventions demonstrated highly significant mean effect sizes for all compliance measures. The magnitude of effect ranged from small to large. ES, effect size. Note: Combined Z > 2.0 is significant at P < 0.05. Combined Z > 2.6 is significant at P < 0.01. Combined Z > 3.3 is significant at P < 0.001. Combined Z > 4.0 is significant at P < 0.0001. Number of effect sizes used in calculations is in parentheses.
The two most frequently measured aspects of health outcome, blood pressure readings and hospitalizations, showed nearly the same effect in terms of the unweighted mean. When the weighted mean is considered, however, the effect of compliance interventions on hospitalizations is weaker. Inspection of individual findings showed that the weaker weighted mean is accounted for by the poor results of a single large, nonrandomized study of an unspecified patient group (all hospitalized patients discharged during a specified time). When the host of health outcomes other than blood pressure and hospitalizations were combined (including such diverse measures as survival, disability, pain, ear infecThe effect of interventions on direct complitions, dental and foot problems), the ESs were ance measures, including tracer substances in also comparable to the other categories.
blood and urine and weight change, was stronger ES, effect size. Note: Combined Z > 2.0 is significant at P < 0.05. Combined Z > 2.6 is significant at P < 0.01. Combined Z > 3.3 is significant at P < 0.001. Combined Z > 4.0 is significant at P < 0.0001. Numbers of effect sizes used in calculations is in parentheses.
than that for health outcomes overall (range in mean ES, 0.20-0.30). In terms of the unweighted ES, there is evidence that interventions were more effective in improving drug or diet adherence through blood/urine tracers than directly through weight change. When the weighted ES is inspected for the two subcategories, the effect was similar.
Interventions had the strongest effect on indirect indicators of drug use. Inspection of the two subcategory measures, pill counts and refill records, showed substantially different patterns of effect. This difference could mean that compliance interventions had a much greater effect on refill behavior than actual pill consumption. Because the pill count and refill data came from different studies, however, one cannot be sure that the difference is due to which outcome is used rather than other study features. Inspection of individual findings showed that randomization was associated with somewhat weaker ESs for both pill counts and refill studies, but did not account for the large ES differences between the two. For nonrandomized refill studies (n = 7), the unweighted r = 0.67, the weighted r = 0.62, and the combined Z = 22.8 (P < 0.00001). For randomized refill studies (n = 9), the unweighted mean r = 0.55, the weighted r = 0.79, and the combined Z = 19.2 (P < 0.00001). For pill count studies, randomization made relatively little difference. For the nonrandom pill count studies (n = 9), the unweighted r = 0.28, the weighted r = 0.26, and the combined Z = 5.37 (P < 0.0001). For the randomized pill count studies (n = 26), the unweighted r = 0.28, the weighted r = 0.13, and the combined Z = 10.3 (P < 0.0001).
Utilization consists of making and keeping appointments and participating in and using preventive screening services (Pap, colon screening, mammography, and vaccination). The magnitude of effect on overall utilization was small to medium in magnitude, as also displayed in Table 1 . Inspection of the subcategories of utilization showed a stronger effect for appointment making than appointment keeping or participation in preventive activities. The unweighted ES was stronger than the weighted ES; the difference is accounted for by a single large study that produced a substantially weaker result than the smaller preventive studies. Subjective compliance measures primarily were concerned with self-report of medication use, although diet, exercise, and self-care activities also were sometimes measured (not often enough to merit separate analysis). The overall effect of interventions on self-reported compliance was small and in the range of ESs for other outcomes.
Prog-iammaaic Focus
The programmatic focus of interventions was coded as either solely educational, behavioral, affective or in various combinations of these elements. Provider-targeted interventions were dealt with separately. As is evident from Refill studies showed substantially stronger effects than did pill count studies. Behavioral interventions showed a somewhat stronger effect on refills than educational interventions when unweighted ES was considered (behavioral mean = 0.58, educational mean = 0.49). Weighted means for educational and behavioral interventions, however, were the same (0.49).
Also notable on Table 2 are medium size effects for affective or affective combination interventions on direct measures of compliance and affective combinations on utilization. It should be noted that affective interventions are uncommon and that the sample size of effects for these calculations was small.
As is evident in Table 2 , single-focus interventions tended to produce smaller effects than multiple-focus interventions. Not reflected in the table is that some single-focus interventions incorporated more than one strategy into their intervention. For instance, an educational intervention might include two different educational strategies: one-to-one education of patients and group education, or written and audiovisual materials. Behavioral interventions might include such things as packaging changes, dose simplification, or skill-building strategies.
For refills and pill count, two or more strategies were used in four behavioral and four educational interventions. In each case, the addition of a second strategy enhanced the intervention's effect on compliance. Two or more educational strategies were stronger ( Similarly, behavioral interventions with two or more strategies (unweighted r = 0.27 and weighted r = 0.25) were stronger than single behavioral interventions (unweighted r = 0.14 and weighted r = 0.18). No obvious advantage for a second strategy was found for health outcomes or subjective measures in either educational or behavioral interventions. There were not enough instances of multiple strategy interventions to make this assessment for direct measures.
Provider interventions showed a moderate effect on indirect measures, specifically pill count. The effect of provider interventions was also evident for utilization, primarily preventive visits, and appointment keeping. The marked discrepancy between the weighted and unweighted ES in this category was accounted for by a very small, but highly significant, effect size in a prevention services study conducted on a population of more than 27,000 subjects. Effects of provider-targeted interventions for health outcomes and subjective compliance reports were very small and not significant.
Effectiveness of Specific Strategies
Although many different strategies were used in the interventions (see Appendix C), relatively few were tested in the absence of other strategies often enough to establish their independent effect on compliance. Nevertheless, some conclusions about the relative effectiveness of individual strategies can be drawn by examining Table 3.  Looking down columns on Table 3 , the strongest and most consistent effects were evident for indirect measures. One-to-one educational instruction, which generally showed small effect on other outcomes, produced moderate effects on refills and pill count measures. Inspection of individual findings showed that refill outcomes were substantially stronger than pill counts. The difference between weighted and unweighted ESs in the one-to-one education category was accounted for by two strong refill ESs, which were based on large samples. Behavioral strategies were also moderately successful in achieving compliance effects for indirect measures. Packaging and dosage simplification were effective in the address of both pill count and refill measures, whereas mailed reminders were used exclusively with refill measures. The weaker weighted ES relative to unweighted ES for packaging was accounted for by one very large study that produced a highly significant but very small effect. Table 2 , utilization outcomes were more strongly affected by educational interventions than behavioral ones. More specifically, it appears that telephone education was especially effective, followed by group and then oneto-one education. Appointment reminders had a relatively weaker impact than educational efforts in terms of ES, although highly significant. The way in which appointment reminders were communicated had little effect on the outcome, with telephone and mail reminders approximately equally effective in enhancing utilization. Rewards or incentives for appointment keeping when used without other interventions were marginally effective and not significant. Although not shown on the table, when rewards were supplemented with educational interventions, the results were much stronger (unweighted r = 0.18 and weighted r = 0.17), combined Z = 5.3, P < o.ooo0001).
As was evident in
Effects for Diagnostic Categories
Interventions addressed a variety of diagnostic categories producing generally small to medium effects, as reflected in Table 4 . Large effects were evident, however, for indirect measures of compliance among patients with diabetes and hyperten-sion. For diabetic patients, inspection of individual findings showed that the interventions had their effect exclusively on refill behavior. For the hypertensive patients, the improvements were evident primarily in terms of pill count. In both instances, the interventions were primarily behavioral in nature. Diabetic patients also benefited from interventions in direct compliance measures (both weight loss and blood test measures) and in self-reported compliance. For patients with hypertension, medium effects were evident in utilization measures, and these were exclusively for appointment keeping. Although small in magnitude of ES, health outcomes for hypertensive patients were impressive and indicated clinically significant improvements in disease management as reflected in blood pressure readings.
Health outcome effects for cancer patients were especially noteworthy and reflected improvements in survival and relapse outcomes. Cancer patients also showed improved drug compliance through direct assessment (urine tracers), in self-reported improvements of compliance, and in enhanced appointment keeping. The predominant focus of cancer interventions was educational and affective.
Interventions targeting patients with mental health problems were successful across the board, with small to medium effects. The health outcomes for these patients reflected reductions in hospitalizations. Consistent with reductions in hospital stay was improved appointment keeping. This improvement most often was accomplished through reminders and education.
The only diagnostic category exclusively applied to children, otitis media, showed moderate effects for pill count and small effects for appointment keeping and subjective reports. The direct indicators of compliance were not significant.
Knowledge Outcomes
Several of the interventions measured knowledge outcomes as well as compliance. Overall, knowledge gains were moderate and significant (weighted r = 0.31, combined Z = 15.4, P < 0.0001). As one might expect, educational interventions that used two different strategies achieved higher knowledge gains than those using one-strategy interventions (weighted r = 0.42 and 0.33, respectively). Large knowledge effects were especially evident across the diagnostic categories. Most notable were knowledge gains for patients with diabetes and mental health problems (weighted r = 0.61 and 0.52, respectively), followed by medium effects for hypertension (weighted r = 0.32) and unspecified diagnoses (weighted r = 0.30). Effects were in the small magnitude range for other diagnostic categories (eg, asthma, cancer, and cardiovascular disease; range of weighted r = 0.16-0.25).
Discussion
Compliance studies vary significantly, and definitions of intervention success vary from outcome-oriented markers of compliance (eg, health outcomes or tracer substances in blood or urine) to process-oriented assessments (eg, refill records, pill counts, and utilization) to subjective perceptions (patient or physician report of compliance) to cognitions (patient knowledge). The indicators of compliance are not equivalent; the measures tap different dimensions of the compliance problem and reflect varied levels of effort and commitment. Although the studies clearly indicated significant beneficial effects to patients, the magnitude of effects and their clinical and practical significance depended on the compliance definition and the nature of the intervention.
The effects reviewed ranged from generally small to occasionally medium and even large, and they were almost always statistically significant in the aggregate. Even the smallest ES noted for health outcomes (weighted r = 0.10 for hospitalizations) was clinically relevant when considered in terms of the binomial effect-size display (BESD). The weighted r of 0.10 (generally considered low in strength) represented a difference of 10% between intervention and control groups, or a "success rate" of 55% among intervention subjects versus 45% in control subjects, reflecting better hospitalization outcomes (assuming equal marginal frequencies). Even this modest achievement can save considerable cost and suffering. For direct compliance measures (blood/urine and weight change indicators), the BESD corresponding to the weighted r of 0.23 (low to moderate in strength) represented a difference of 23% between intervention and control groups, or a "success rate" of 62% among intervention subjects versus 38% in control subjects.
For the most part, the unweighted effects were larger than weighted effects, reflecting a tendency for larger programs to produce weaker effects. Although we cannot interpret this nonexperimental comparison with confidence, we speculate that smaller studies are likely to have had more homogeneous populations than larger studies and may have allowed for more precisely tailored interventions. It is also possible that smaller sample studies used more resource-intensive interventions or were better controlled and monitored. The three largest studies were designed to increase use of preventive services and were directed toward many thousands of patients; indeed, the largest study targeted more than 75,000 people in an attempt to increase utilization of Pap tests (all women without a Pap test in the previous 9 years). The various interventions used in these large studies, physician education and updating on patient Pap status, were only very modestly successful (r range = 0.03-0.08). These largest prevention studies were nonrandomized trials. Although the average unweighted effect sizes for all compliance outcomes for randomized and nonrandomized studies were almost identical (r = 0.23 and r = 0.25, respectively), differences in the magnitude of the weighted effect sizes were evident, with the large nonrandomized studies being substantially weaker (r = 0.08) than the randomized studies (r = 0.21).
For the most part, results within the groupings of compliance indicators were relatively similar, with the exception of indirect measures and utilization. Studies using refill records as the outcome measure showed substantially larger effects than pill count, as did studies monitoring appointment making compared with appointment keeping. Several explanations are possible. First, filling prescriptions and making appointments demand only limited commitment and may more accurately reflect intention to comply than actual compliance. Refill records showed a dramatically higher ES than pill counts, suggesting that people fill their prescriptions more readily than they consume their medicine. Likewise, encouraging appointment making appears easier than achieving improved appointment keeping. There are a variety of external issues affecting utilization, including such barriers as transportation, cost, and competing time demands. The success of appointment making interventions may reflect patients'desire to cooperate with recommendations to seek care, but inability to follow through when faced with practical barriers.
Inspection of the programmatic focus of interventions demonstrated that the more comprehensive the program, the stronger the outcome. Combined-focus interventions were generally more effective than those with a single focus, especially educational/behavioral. Three-focus interventions, including those with educational, behavioral, and affective components, were the strongest of combined-focus programs, although used in only a handful of studies. Of the singlefocus interventions, behavioral and educational approaches appeared approximately equally effective and generally stronger than solely affective interventions.
Although not directly parallel to the analysis of the programmatic focus of the interventions, simply inspecting the number of different strategies used in an intervention supports the contention that programs that were more comprehensive were more effective. Two educational or behavioral strategies were generally better than one, although this was not always the case.
A more detailed inspection of individual intervention strategies showed that written materials were weaker than other educational interventions. Group education produced moderately strong effects for both direct measures of compliance and utilization, whereas telephone education was especially effective in utilization. Interestingly, appointment reminders communicated through the telephone were not any more effective in improving utilization than mailed reminders. Considering the resource-intensive nature of telephone reminders relative to mailed reminders, the latter may be considered as a more attractive alternative.
Of the behavioral strategies, packaging seemed to produce strong effects on refill and pill count measures, but dosage and mailed reminders were also effective in enhancing these outcomes. The provision of rewards as a compliance intervention was not studied frequently enough to draw firm conclusions. There was an indication that rewards were more effective if combined with educational or affective components than when offered in isolation. A recent review of financial incentives to promote compliance by Giuffrida and Torgerson15 found a positive effect in 10 of the 11 randomized studies they reviewed. Using the information presented by the authors in their review, we estimated the r associated with these interventions to be 0.16 unweighted, 0.15 weighted, with a combined Z value of 11.0, P < 0.0001. This is quite close to our own estimate of the effectiveness of rewards when supplemented by additional intervention strategies, an aspect of evaluation not considered in the Giuffrida and Torgerson review.
The effects of provider-targeted interventions on patient compliance were mixed, with very weak as well as moderate effects. Provider interventions were more successful in inspiring patient compliance in terms of pill count and utilization than in appointment keeping and use of prevention services. Despite the tendency of preventive services interventions to produce very small ESs, however, their population-based impact was quite substantial.
There was a differential impact of compliance interventions on various diagnostic groupings; especially notable were health and direct effects evident for cancer patients, as well as for patients with hypertension, diabetes, and mental health problems. Moreover, strong effects were evident for diabetic and hypertensive patients when refill behavior and pill count methods were used to gauge intervention success. Interventions also produced strong effects on knowledge, again evident for patients with diabetes as well as those with mental illness. These associations can be interpreted in light of recent results of the Medical Outcomes Study. Positive correlations between compliance and health outcomes were evident only among insulin-dependent diabetic patients.21'22 Our findings suggest that compliance interventions also were related to meaningful outcomes for patients with cancer, hypertension, and mental health problems. Having summarized the effects of compliance interventions, it is appropriate to revisit the question of effect magnitude. We have commented so far on the size of the effects in terms of the "small," "medium,"and "large"rules of thumb as well as in terms of the BESD developed by Rosenthal and Rubin.20 The evaluation of effect magnitude is a relative matter, and one must ask about the practical meaning and usefulness of even small effect size estimates because the clinical and practical significance of an effect size is not necessarily tied to the magnitude of effects. Rosenthal's observations about this provide an important perspective.17 In analyzing the results of two randomized clinical trials that were ended prematurely because of ethical concerns about denying incontrovertible benefit to patients receiving the placebo, Rosenthal calculated the effect sizes to be extremely small. In the case of the physicians' aspirin study for the prevention of heart attack, Rosenthal's calculated effect size r was 0.03, and in the trial of propranolol as beneficial treatment for heart attack, the effect size r was 0.04. Further, even when "breakthrough" drugs, such as AZT in the treatment of AIDS patients or cyclosporine for prevention of organ rejection, were looked at in terms of the effect size r, the results were a modest 0.23 and 0.19, respectively. When these results are interpreted in the BESD framework, in terms of an important and valued outcome such as lives saved or heart attacks averted, however, even very small effect sizes were clinically impressive.
Further 
Conclusions
We can draw four generalities from this body of literature:
First, compliance interventions had a weak to moderate statistical effect on indicators of patient compliance, but represented generally efficacious interventions in practical terms.
Second, no single intervention strategy appeared consistently stronger than any other. There were no magic bullets evident in our review; direct education, group processes, familial support, behavioral modalities, or provider interventions showed no substantial advantage over one another. Moreover, mixed programmatic focus interventions were more effective than single-focus interventions. The more comprehensive the program, the more effective the outcome, and the most powerful combinations included all three elements-educational, behavioral, and affective. We agree with Mullen et al's8 conclusions based on their review of the health education literature that there is no obvious superiority of one strategy compared with any other. Two health education axioms, that people learn in different ways and that a variety of teaching approaches increases learner interest, have been validated.24
Third, the compliance interventions showed stronger benefits for patients with particular conditions. The effects were quite striking for diabetes; more moderately so for asthma, cancer, hypertension, mental illness; and weaker for conditions such as otitis media and unspecified conditions (usually infections for which antibiotics were prescribed). These findings may be a function of the number of studies conducted in these areas, which limits our ability to generalize findings, but also may suggest that enhancement of compliance for some conditions is either more difficult or less efficacious in producing positive patient outcomes than for other conditions. Finally, the compliance intervention studies conducted so far have been much too narrow and limited. The field would benefit from a broader outcome context, that is, interventions should be designed not only to improve compliance but also to address the broader spectrum of patient outcomes so valued by health services researchers such as satisfaction, patient empowerment, comprehension and understanding, as well as markers of clinical significance including quality of life, functional status, and enhancement of emotional health and well-being. The results of a prior metaanalysis relating physician communication behaviors to patient outcomes can be instructive in this regard.25 More information giving and more positive talk, but less negative talk and fewer questions overall (but more questions about compliance in particular), predicted higher patient compliance. The review also found that the length of visit, the amount of information given, the degree of partnership building, and the amount of positive talk in the visit were all predictors of patient satisfaction. Patient recall and comprehension also were associated with physicians' communication (more information giving, more positive talk, more partnership building, and less question asking).
Additional evidence linking physicians' communication behaviors to patient health outcomes is provided by a comprehensive review of 21 randomized clinical trials and analytic studies of communication interventions.26 Physician informativeness, partnership building, and emotional rapport and support were identified in the review as associated with a variety of health outcomes. Included among these were improvements in emotional health, symptom resolution, physical functioning and quality of life assessments, as well as those measures used in the current metaanalysis such as physiologic indicators of disease management (ie, blood pressure and blood sugar level) and pain control. Our results suggest that the effort it takes to build rapport with a patient can lead to a significant improvement in the level of compliance with a treatment protocol that the patient achieves. The more comprehensive the compliance intervention, the more likely it is to be successful.
